Trial Profile
Effect of SGLT2 inhibition on coronary microvascular function in type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2020
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- 03 Apr 2019 Status changed from recruiting to completed.
- 04 May 2017 New trial record